Efficacy and Toxicity of Rituximab in Multiple Sclerosis
Author:
Publisher
Briefland
Subject
Psychiatry and Mental health,Neurology (clinical),General Neuroscience
Reference35 articles.
1. Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys
2. B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
3. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
4. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions;Endocrine, Metabolic & Immune Disorders - Drug Targets;2021-10
2. Neuroprotective Methodologies in the Treatment of Multiple Sclerosis Current Status of Clinical and Pre-clinical Findings;Current Drug Discovery Technologies;2021-02-10
3. Infusion-Related, Short-term, and Delayed Side Effects of Rituximab in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder;Shiraz E-Medical Journal;2020-11-25
4. Pharmacotherapy of Prograf (Tacrolimus) in Liver Transplant Recipients; Consideration of Its' Levels with Efficacy and Toxicity;Jentashapir Journal of Health Research;2017-02-25
5. Multiple sclerosis is accompanied by lack of KIR2DS1 gene: A meta-analysis;Genomics Data;2016-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3